or Try an Advanced Search...

    Technical Analysis for PTN - Palatin Technologies, Inc.

    Grade Last Price % Change Price Change
    C 2.05 -1.44% -0.03
    PTN closed down 1.44 percent on Wednesday, May 8, 2024, on 12 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    Earnings due: May 14
    *** please verify all earnings dates ***
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Up
    Historical PTN trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Inside Day Range Contraction -1.44%
    Upper Bollinger Band Touch Strength -1.44%
    Bearish Engulfing Bearish 2.50%
    MACD Bullish Centerline Cross Bullish 2.50%
    Outside Day Range Expansion 2.50%
    Upper Bollinger Band Touch Strength 2.50%
    New Uptrend Bullish -2.84%
    Older End-of-Day Signals for PTN ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 15 hours ago
    Possible Inside Day about 15 hours ago
    60 Minute Opening Range Breakout about 18 hours ago
    Down 2 % about 19 hours ago
    Down 1% about 19 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    PTN Chart by TradingView
    Basic chart:

    Profile

    Palatin Technologies, Inc., a biopharmaceutical company, engages in the development of peptide therapeutics for the treatment of diseases. Its drug development programs include Bremelanotide, a peptide melanocortin receptor agonist that is in Phase IIb clinical trials for the treatment of female sexual dysfunction; and PL-3994, a peptide mimetic natriuretic peptide receptor A agonist, which is in Phase I clinical trials for the treatment of cardiovascular and pulmonary indications, as well as melanocortin receptor-based compounds for treatment of obesity. The company was founded in 1986 and is based in Cranbury, New Jersey.
    Classification
    Sector: Healthcare
    Industry: Diagnostics & Research
    Keywords: Biopharmaceutical Disease Molecular Biology Drug Development Obesity Dysfunction Endocrine System Peptides Male Sexual Dysfunction Melanocortin Sexual Dysfunction Treatment Of Obesity

    Is PTN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 2 Palatin gets FDA OK to test weight loss therapy with Eli Lilly’s tirzepatide
    May 2 Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
    Apr 30 Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
    Apr 14 10 Micro-Cap Healthcare Stocks Insiders Are Buying
    Apr 12 Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying
    Apr 9 Palatin (PTN) Up 15% on Results From Dry Eye Disease Study
    Apr 8 Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data
    Apr 8 Palatin stock jumps 16% on positive Phase 3 data for eye drug
    Apr 8 Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
    Mar 14 Palatin files to sell 1.92M shares of common stock for holders
    See more PTN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.65
    52 Week Low 1.43
    Average Volume 624,694
    200-Day Moving Average 2.35
    50-Day Moving Average 1.82
    20-Day Moving Average 1.89
    10-Day Moving Average 1.94
    Average True Range 0.18
    RSI (14) 55.95
    ADX 28.3
    +DI 27.53
    -DI 11.47
    Chandelier Exit (Long, 3 ATRs) 1.69
    Chandelier Exit (Short, 3 ATRs) 2.19
    Upper Bollinger Bands 2.13
    Lower Bollinger Band 1.65
    Percent B (%b) 0.83
    BandWidth 25.40
    MACD Line 0.03
    MACD Signal Line -0.01
    MACD Histogram 0.0425
    Fundamentals Value
    Market Cap 33.08 Million
    Num Shares 16.1 Million
    EPS -2.15
    Price-to-Earnings (P/E) Ratio -0.95
    Price-to-Sales 11.87
    Price-to-Book 4.25
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.16
    Resistance 3 (R3) 2.16 2.13 2.14
    Resistance 2 (R2) 2.13 2.10 2.13 2.13
    Resistance 1 (R1) 2.09 2.09 2.08 2.09 2.13
    Pivot Point 2.06 2.06 2.05 2.06 2.06
    Support 1 (S1) 2.02 2.03 2.01 2.02 1.97
    Support 2 (S2) 1.99 2.02 1.99 1.97
    Support 3 (S3) 1.95 1.99 1.96
    Support 4 (S4) 1.95